Lifeforce has a page specifically titled Micronized Progesterone. That is a more direct term match than a general menopause menu, but a title is still only one part of a medicine description. It does not automatically tell a reader the route, manufacturer, complete ingredients or approval status of the preparation a clinician might recommend.
We reviewed that page alongside Lifeforce’s menopause-management and membership information on September 29, 2026. The pages document a clinical offer, while leaving product and purchase questions that should not be filled in by assumption. Their price and testing descriptions also differ. This review retains those differences instead of selecting the most attractive version as a confirmed offer.
Read this article by section
The named ingredient sits within a clinical service
The Micronized Progesterone page connects the item with Lifeforce’s care and diagnostic process. It is not evidence of unrestricted retail access to a prescription medicine. A clinician must determine whether a treatment is appropriate, and the service’s access conditions still matter. The reviewed page does not establish an exact oral capsule manufacturer or a guaranteed pharmacy supply. Our Hone Health review concerns a description that explicitly identifies a compounded oral capsule. Those are different levels of public product detail; they should remain different when a reader compares what has actually been documented.
Micronized cannot stand in for the rest of the label
The word in Lifeforce’s product title does not establish every characteristic of the finished medicine. In the exact Prometrium labeling, micronization appears alongside oral administration, specific capsule strengths and an ingredient list. The label also qualifies the bioavailability discussion. It cannot be treated as the missing Lifeforce label. Our micronized terminology guide makes the same distinction between describing a property and identifying a preparation. A useful request to the service would ask for the proposed product name, route and dispensing details together, rather than merely asking whether the hormone has been micronized.
Soy and peanuts wording leaves a formulation question open
The reviewed Lifeforce page carries a notice referring to soy and/or peanuts. That wording does not identify which ingredient is present in which proposed formulation, nor does it supply a complete list. It should not be converted into either an allergy clearance or a precise claim about a particular oil or capsule shell. The exact FDA Prometrium label provides product-specific peanut information, but there is no verified basis to assume Lifeforce supplies that product. A pharmacist needs the actual prescription and preparation to answer an ingredient question. The ambiguity belongs in the review until a preparation-specific record resolves it. It is reasonable to ask for the information before agreeing to a proposed prescription, rather than trying to decode the warning from a product photograph or title. The reply should distinguish an ingredient in the actual preparation from a general caution applied across several possible products. If the service changes the proposed manufacturer or pharmacy, the earlier ingredient answer should not silently be treated as an answer for the replacement. A pharmacist can address that specific record without the website making a personal safety determination.
Clinical benefit language exceeds what the title can prove
Lifeforce’s product description presents broad symptom-relief claims. Those statements do not demonstrate the outcomes of an identifiable finished product in a defined study population. A hormone name also does not tell a reader whether the proposed use is a labeled indication or another clinical use. The approval guide separates that question from chemical identity, while the route guide avoids transferring evidence between ways of administering progesterone. The clinician should explain the intended benefit and the limits of the supporting evidence for the actual proposal. This review has no patient-outcome data from Lifeforce.
The reviewed pages do not present one settled membership price
The progesterone page describes a $149 monthly membership and a $599 Diagnostic. The separate menopause-management page displays $99 per month. These are competing published descriptions, not amounts that this review can reconcile into a single current contract. The menopause page also combines different testing descriptions, including an 11-plus-marker presentation with three tests in the first year and two thereafter, alongside broader 50-plus-marker and quarterly language. The membership page adds quarterly testing language. Ask which written plan, testing schedule and separate medicine charges apply before calculating ongoing spending.
Compare complete terms, rather than neighboring headline numbers
The Fountain review illustrates another price-reading issue: advertised equivalents tied to bills covering specified numbers of weeks. Lifeforce’s uncertainty is different, because the reviewed plan pages do not resolve which offer applies. A lower headline cannot be taken as an individual quote or a promise that progesterone is included. Ask for the amount charged now, the next bill, what each period covers and the cancellation rules for that selection. Availability, medicine charges and laboratory inclusions should be written beside those amounts. This comparison does not choose a plan or assume that either service proposes the same preparation.
Two missing records would answer different questions
Lifeforce needs to clarify both the treatment record and the purchase record for an individual proposal. The product page supplies a name but not all formulation details; the membership information supplies program descriptions without resolving every conflicting figure. The clinician and pharmacy can address the first set of questions, while the service should confirm the selected agreement in writing. Neither record substitutes for the other. Until then, this review supports the existence of a clinician-led menopause offer and a named micronized-progesterone page, with the route, exact ingredients, regulatory category and final financial commitment still requiring confirmation.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Lifeforce: Micronized ProgesteroneProvider product description, soy/peanut allergy notice and access terms; exact oral capsule, manufacturer and complete excipients not established · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29
- Lifeforce: Menopause ManagementProvider menopause service and plan descriptions; different membership and testing statements remain unreconciled · Checked 2026-09-29
- Lifeforce: Become a memberProvider recurring membership services and support roles; not a personal testing schedule or capsule price · Checked 2026-09-29